Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens

Claudia Marchetti; Filippo Bellati; Angela Musella; Chiara Napoletano; Giorgia Perniola; Violante Di Donato; Sandro Pignata; Marianna Nuti; Pierluigi Benedetti Panici

doi:10.1007/s10147-011-0300-9

Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens

Int J Clin Oncol. 2012 Aug;17(4):385-9. doi: 10.1007/s10147-011-0300-9. Epub 2011 Sep 3.

Authors

Claudia Marchetti¹, Filippo Bellati, Angela Musella, Chiara Napoletano, Giorgia Perniola, Violante Di Donato, Sandro Pignata, Marianna Nuti, Pierluigi Benedetti Panici

Affiliation

¹ Department of Gynecology and Obstetrics, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

PMID: 21892670
DOI: 10.1007/s10147-011-0300-9

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

CA-125 Antigen / blood
Carboplatin / administration & dosage*
Disease-Free Survival
Drug Administration Schedule*
Female
Humans
Membrane Proteins / blood
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / pathology
Ovarian Neoplasms / surgery
Paclitaxel / administration & dosage*

Substances

CA-125 Antigen
MUC16 protein, human
Membrane Proteins
Carboplatin
Paclitaxel